In an intriguing hypothetical scenario, the US could buy Novo Nordisk for its current market capitalization of $606 billion. While this might initially sound like an outlandish idea, it offers some noteworthy benefits, such as providing the Centers for Medicare & Medicaid Services (CMS) direct access to insulin manufacturing. This is akin to California’s plans to create state-manufactured insulin and includes acquiring land in the sought-after nature park of Viborg, Denmark.

A Financial and Strategic Analysis

Purchasing Novo Nordisk may appear to be a fantastical notion, reminiscent of something from Alice in Wonderland. However, consider the current reality: Medicare often pays exorbitant amounts for single drugs, sometimes surpassing the total retail drug spending.

Let’s break down the numbers. If Medicare and Medicaid coverage were expanded to include all beneficiaries who are overweight or obese, the cost of purchasing Novo Nordisk could be recouped within just 22 months through savings on GLP-1 drug purchases alone. This rapid return on investment highlights the potential financial viability of such a bold move.

Learning from the Past: The Gilead Proposal

This isn’t the first time a radical acquisition has been suggested to address high drug costs. In 2014, when Gilead’s sofosbuvir hit the market for hepatitis C treatment at $84,000 per patient, there were calls for the federal government to buy the company outright. The aim was to control spiraling healthcare costs and ensure more affordable access to essential medications.

Potential Benefits Beyond Cost Savings

Beyond the immediate financial savings, owning Novo Nordisk could provide the US government with several strategic advantages:

1. Manufacturing Capacity for Insulin: Direct control over insulin production would help stabilize and potentially reduce prices, addressing a long-standing issue of affordability for diabetic patients.
2. Investment in Public Health: The acquisition could pave the way for more government-led innovations in pharmaceuticals, fostering a more sustainable and equitable healthcare system.
3. Environmental and Economic Benefits: Owning land in Viborg, Denmark, known for its beautiful nature parks, could have additional environmental and recreational benefits, potentially enhancing public health and well-being.

A Bold Step for Healthcare Reform

While buying Novo Nordisk might seem like an audacious and unconventional proposal, it underscores the need for innovative solutions to tackle the high cost of healthcare. By exploring such radical ideas, we can push the boundaries of traditional thinking and potentially discover viable paths to more affordable and effective healthcare solutions.

While the proposal to buy Novo Nordisk is undoubtedly bold, it is not without merit. As healthcare costs continue to rise, particularly for essential medications, we must remain open to exploring all possibilities, no matter how unconventional they may seem.